← Back to RNAZ

TransCode Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 14/08/2026Mar 2026Filed 14/08/2026Sep 2025Filed 14/11/2025Jun 2025Filed 14/08/2026Mar 2025Filed 14/08/2026Sep 2024Filed 14/11/2025Jun 2024Filed 14/11/2025Mar 2024Filed 14/11/2025
−$6.8−$18−$4.9−$4.3−$12−$2.3−$5.2−$3.3
−$7.17−$21.28−$5.82−$5.13−$70.16−$146.06−$680.23−$21.35
10.90.80.8

Trend

Net income

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.